Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2018, Article ID 1614683, 7 pages
https://doi.org/10.1155/2018/1614683
Research Article

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility

1Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
2Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
3Department of Endocrinology, Jiangsu Province Hospital of TCM, 155 Hanzhonglu, Jiangsu Nanjing 210029, China

Correspondence should be addressed to Jie Pan; moc.361@napyknap and Chen Fang; moc.anis@1199afa

Received 11 April 2018; Accepted 15 October 2018; Published 11 November 2018

Academic Editor: Marco Songini

Copyright © 2018 Chenyue Qian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Tian, Y. Liu, Y. Liu, K. Chen, and S. Lyu, “Cellular and molecular mechanisms of diabetic atherosclerosis: herbal medicines as a potential therapeutic approach,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 9080869, 16 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. B. T. Fife and J. A. Bluestone, “Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways,” Immunological Reviews, vol. 224, no. 1, pp. 166–182, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Fujisawa, F. Haseda, C. Tsutsumi et al., “Low programmed cell death-1 (PD-1) expression in peripheral CD4+ T cells in Japanese patients with autoimmune type 1 diabetes,” Clinical & Experimental Immunology, vol. 180, no. 3, pp. 452–457, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Nolan, P. Savas, A. N. Policheni et al., “Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer,” Science Translational Medicine, vol. 9, no. 393, article eaal4922, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Bang, T. J. Wilhite, L. R. G. Pike et al., “Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 98, no. 2, pp. 344–351, 2017. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Marwitz, S. Scheufele, S. Perner, M. Reck, O. Ammerpohl, and T. Goldmann, “Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression,” Clinical Epigenetics, vol. 9, no. 1, p. 51, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Wu, Y. Zhu, J. Jiang, J. Zhao, X. G. Zhang, and N. Xu, “Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance,” Acta Histochemica, vol. 108, no. 1, pp. 19–24, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Zou and L. Chen, “Inhibitory B7-family molecules in the tumour microenvironment,” Nature Reviews Immunology, vol. 8, no. 6, pp. 467–477, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. Q. Li, J. F. Gao, and B. L. Qi, “PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin chemotherapy by promoting apoptosis,” Journal of Balkan Union of Oncology, vol. 22, no. 3, pp. 746–756, 2017. View at Google Scholar
  10. J. Y. Kim, E. Lee, K. Park et al., “Immune signature of metastatic breast cancer: identifying predictive markers of immunotherapy response,” Oncotarget, vol. 8, no. 29, pp. 47400–47411, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. M. J. I. Ansari, A. D. Salama, T. Chitnis et al., “The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice,” Journal of Experimental Medicine, vol. 198, no. 1, pp. 63–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Hughes, N. Vudattu, M. Sznol et al., “Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy,” Diabetes Care, vol. 38, no. 4, pp. e55–e57, 2015. View at Google Scholar
  13. J. Martin-Liberal, A. J. S. Furness, K. Joshi, K. S. Peggs, S. A. Quezada, and J. Larkin, “Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report,” Cancer Immunology, Immunotherapy, vol. 64, no. 6, pp. 765–767, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Dai, R. Jia, X. Zhang, Q. Fang, and L. Huang, “The PD-1/PD-Ls pathway and autoimmune diseases,” Cellular Immunology, vol. 290, no. 1, pp. 72–79, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. E. V. Dmitrieva-Zdorova, M. V. Gabaeva, Y. A. Seregin, N. V. Bodoev, and O. E. Voronko, “PDCD1 PD-1.3 polymorphism and allergic bronchial asthma in Russian and Buryat patients,” Journal of Asthma, vol. 54, no. 1, pp. 46–52, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Chua, L. Lian, X. Sim, T. Cheah, and T. Lau, “Association between PDCD1 gene polymorphisms and risk of systemic lupus erythematosus in three main ethnic groups of the Malaysian population,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 9794–9803, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Yang, Y. Zou, Y. Bai, and M. Li, “The programmed cell death 1 gene polymorphisms (PD 1.3 G/A, PD 1.5 C/T and PD 1.9 C/T) and susceptibility to ankylosing spondylitis: a meta-analysis,” Journal of Orthopaedic Science, vol. 20, no. 1, pp. 55–63, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Zhang, Y. Li, X. Zhong, W. Huang, L. Nie, and W. Zhang, “Establishment of retinoblastoma model in NOD-SCID mice and study of metastasis,” Yan Ke Xue Bao, vol. 21, no. 3, pp. 185–191, 2005. View at Google Scholar
  19. J. Wang, T. Yoshida, F. Nakaki, H. Hiai, T. Okazaki, and T. Honjo, “Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 33, pp. 11823–11828, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. L. Colli, J. L. E. Hill, L. Marroquí et al., “PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-α and-γ via IRF1 induction,” EBioMedicine, vol. 36, pp. 367–375, 2018. View at Publisher · View at Google Scholar
  21. C. Pizarro, D. F. García-Díaz, E. Codner, F. Salas-Pérez, E. Carrasco, and F. Pérez-Bravo, “PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile,” Diabetes/Metabolism Research and Reviews, vol. 30, no. 8, pp. 761–766, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. H. Lee, S. C. Bae, J. H. Kim, and G. G. Song, “Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility,” Zeitschrift für Rheumatologie, vol. 74, no. 3, pp. 230–239, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Hiromine, H. Ikegami, T. Fujisawa et al., “Trinucleotide repeats of programmed cell death-1 gene are associated with susceptibility to type 1 diabetes mellitus,” Metabolism, vol. 56, no. 7, pp. 905–909, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. R. B. Denman, “Using RNAFOLD to predict the activity of small catalytic RNAs,” BioTechniques, vol. 15, no. 6, pp. 1090–1095, 1993. View at Google Scholar
  25. H. Dong, S. E. Strome, D. R. Salomao et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion,” Nature Medicine, vol. 8, no. 8, pp. 793–800, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Wang, F. Li, Y. Mao et al., “A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma,” Human Genetics, vol. 132, no. 6, pp. 641–648, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. L. H. Tao, X. R. Zhou, F. C. Li et al., “A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer,” Cancer Immunology, Immunotherapy, vol. 66, no. 3, pp. 309–318, 2017. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Du, J. Zhu, Y. Chen et al., “Variant SNPs at the microRNA complementary site in the B7-H1 3-untranslated region increase the risk of non-small cell lung cancer,” Molecular Medicine Reports, vol. 16, no. 3, pp. 2682–2690, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Nomizo, H. Ozasa, T. Tsuji et al., “Clinical impact of single nucleotide polymorphism in PD-L1 on response to nivolumab for advanced non-small-cell lung cancer patients,” Scientific Reports, vol. 7, no. 1, article 45124, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. X. L. Shi, S. Mancham, B. E. Hansen et al., “Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction,” Journal of Hepatology, vol. 64, no. 6, pp. 1274–1282, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Y. Lee, D. K. Jung, J. E. Choi et al., “Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer,” Gene, vol. 599, pp. 28–35, 2017. View at Publisher · View at Google Scholar · View at Scopus